Know the Dates: How to Forecast Drug Patent Expiry by Country for Smarter Portfolio Planning
The Calendar Is Your Competitive Weapon Every pharmaceutical company has a patent expiry problem. Not because patents expire — that […]
The Manufacturing Moat: Why Process Patents Are the Most Undervalued Defense Against Generic Entry
The Hierarchy Problem in Pharmaceutical IP Every pharmaceutical patent portfolio has a hierarchy, whether the company managing it acknowledges one
Don’t Get Burned: 3 Critical Patent Due Diligence Steps Before Investing in Biotech IPOs
The IPO Trap That Costs Investors Billions Biotech IPOs are uniquely dangerous investments, and not for the reasons most investors
Don’t Get Burned: 3 Critical Patent Due Diligence Steps Before Investing in Biotech IPOs Read Post »
5 Costly Mistakes Companies Make When Modeling Biosimilar Entry Windows
The Model That Cost $2 Billion In the spring of 2018, a major integrated health system’s pharmacy benefit function projected
5 Costly Mistakes Companies Make When Modeling Biosimilar Entry Windows Read Post »
Know Before You File: Using Patent Landscape Analysis to Drive Go/No-Go Decisions in Generic and Biosimilar Drug Development
The $2.6 Billion Mistake Nobody Talks About In 2019, a mid-sized generic pharmaceutical company committed $340 million to develop a
Designing Around the Moat: A Generic Developer’s Guide to Secondary Formulation Patents
When AbbVie filed its 132nd patent on adalimumab, the drug that became Humira, the company was not protecting a new
Designing Around the Moat: A Generic Developer’s Guide to Secondary Formulation Patents Read Post »
Your Pharmaceutical Portfolio Has a Time Bomb in It. Patent Expiration Data Tells You Where
How executives, investors, and analysts use patent cliff intelligence to protect revenue, time acquisitions, and build portfolios that don’t collapse
Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents
Patent expiration is the most predictable crisis in pharmaceuticals. The dates are public, the revenue cliffs are calculable, and yet
Crack the Patent Wall: How Hard Data Beats Big Pharma’s IP Strategy Every Time
Drug companies do not simply invent medicines. They engineer legal structures designed to convert twenty years of patent protection into
Crack the Patent Wall: How Hard Data Beats Big Pharma’s IP Strategy Every Time Read Post »
